Some of the more recent efforts in tuberculosis (TB) and trypanosomiasis drug discovery from both Product Development Partnerships (PDPs) and academia are highlighted in this this volume. Drug discovery approaches include both target- and phenotypic whole cell screening- approaches. Regarding the latter, mechanism of action studies through target identification are also illustrated.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Tuberculosis Steven J. Berthel, Christopher B. Cooper and Nader P. Fotouhi 2. Antituberculosis agents: Beyond medicinal chemistry rules Marco Pieroni 3. Development of MmpL3 inhibitors for tuberculosis treatment Giovanna Poce, Sara Consalvi, Giulia Venditti, Cristina Scarpecci and Mariangela Biava 4. Inhibitors of enzymes in the electron transport chain of Mycobacterium tuberculosis Andrew M. Thompson and William A. Denny 5. Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance Nicolas Willand, Marion Flipo, Baptiste Villemagne, Alain Baulard and Benoit Deprez 6. Sustainable anti-trypanosomatid drugs: An aspirational goal for medicinal chemistry Maria Laura Bolognesi
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
*Required Information
This website uses cookies to ensure you get the best experience. Learn more
